Royalty Pharma plc (RPRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 4:00 PM EDT
Company Participants
Christopher Hite – Chairman of Partnering & Investments
Conference Call Participants
Asad Haider – Goldman Sachs Group, Inc., Research Division
Presentation
Asad Haider
Goldman Sachs Group, Inc., Research Division
All right. Let’s get right into it, to our next session. Very excited to have Chris Hite, Chairman of Royalty Pharma with us here today.
Question-and-Answer Session
Asad Haider
Goldman Sachs Group, Inc., Research Division
Chris, maybe just to tee you up, give us — start with like 10,000 feet for those new to the story, give us a brief history on the evolution of the company, its core players, what the fundamental thesis is and why investors should be looking at Royalty Pharma today?
Christopher Hite
Chairman of Partnering & Investments
Well, first of all, thank you very much for having us here. We’re really delighted to be here at the Goldman Conference and great investor meetings today, and so thank you very much.
So Royalty Pharma was founded about 30 years ago. We’re celebrating our 30th anniversary by our current CEO and Chairman, Pablo Legorreta. The basic premise back then was there’s fragmented innovation across the sector. And that innovation can occur at universities and hospitals and foundations in addition to biotech and pharma companies. And every time that was occurring, ultimately, the foundational research would get licensed out to pharma and a royalty was created. And Pablo was very savvy about approaching these universities and hospitals, about acquiring those royalty streams. And that allowed the company — the university or the hospital that had those roll to streams to take the upfront capital, reploy that, and he would take the risk on the commercial side of those assets.
